Wang Changbin, Dong Xinzhe, Sun Xiaorong, Zhang Ran, Xing Ligang
School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences.
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences.
Nucl Med Commun. 2019 Nov;40(11):1091-1098. doi: 10.1097/MNM.0000000000001076.
Since the discovery of the fact that tyrosine kinase inhibitors could improve progression-free survival for patients with advanced non-small cell lung cancer compared with traditional chemotherapy, it has been extremely important to identify epidermal growth factor receptor mutation status in treatment stratification. Although lack of sufficient biopsy samples limit the precise detection of epidermal growth factor receptor mutation status in clinical practice, and it is difficult to identify the sensitive patients who confer favorable response to tyrosine kinase inhibitors. An increasing number of scholars tried to deal with these problems using methods based on the non-invasive imaging including computed tomography and PET to find the association with epidermal growth factor receptor mutation status and survival treated with tyrosine kinase inhibitor in non-small cell lung cancer. Although the conclusions have not reached a consensus, quantitative and high-throughput radiomics have brought us a new direction and might successfully help identify patients undergoing tyrosine kinase inhibitors who could get significant benefits.
自从发现酪氨酸激酶抑制剂与传统化疗相比可改善晚期非小细胞肺癌患者的无进展生存期这一事实以来，在治疗分层中识别表皮生长因子受体突变状态就变得极其重要。尽管缺乏足够的活检样本限制了临床实践中表皮生长因子受体突变状态的精确检测，并且难以识别对酪氨酸激酶抑制剂有良好反应的敏感患者。越来越多的学者试图使用基于计算机断层扫描和PET等非侵入性成像的方法来处理这些问题，以寻找与非小细胞肺癌中表皮生长因子受体突变状态及酪氨酸激酶抑制剂治疗生存期的关联。尽管结论尚未达成共识，但定量和高通量的放射组学为我们带来了新的方向，并可能成功帮助识别接受酪氨酸激酶抑制剂治疗能获得显著益处的患者。
